GILD

SEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,234

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,704

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · derivative · entry 3

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,995

Underlying: Common Stock · 6,002 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

SEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · nonDerivative · entry 2

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,454

SEC source: 0002110603-26-000010 · wk-form4_1786481458.xml · nonDerivative · entry 1

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,362

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 592,133

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F4 · price: Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 592,733

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F3 · price: Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000028 · wk-form4_1785879633.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 600,433

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F2 · price: Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000022 · wk-form4_1784239680.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,646

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · price: Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000026 · wk-form4_1784235279.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,234

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sale prices for the transactions reported range from $129.45 to $130.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000026 · wk-form4_1783023256.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 607,133

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F3 · price: Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000026 · wk-form4_1783023256.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 610,233

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F2 · price: Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000020 · wk-form4_1781646803.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,646

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,234

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,684

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,754

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,851

Underlying: Common Stock · 2,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,646

SEC source: 0001310204-26-000018 · wk-form4_1781217163.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · derivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,080

Underlying: Common Stock · 8,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 622,133

SEC source: 0001638643-26-000024 · wk-form4_1781216988.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 626,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · derivative · entry 3

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,928

Underlying: Common Stock · 533 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · nonDerivative · entry 2

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,252

SEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · nonDerivative · entry 1

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · derivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,851

Underlying: Common Stock · 2,796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,234

SEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · derivative · entry 3

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,997

Underlying: Common Stock · 589 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · nonDerivative · entry 2

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,360

SEC source: 0002110603-26-000008 · wk-form4_1781217244.xml · nonDerivative · entry 1

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 617,567

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F4 · price: Sale prices for the transactions reported range from $132.71 to $133.295. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 618,605

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F3 · price: Sale prices for the transactions reported range from $131.71 to $132.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000022 · wk-form4_1780437841.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 621,667

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

F2 · price: Sale prices for the transactions reported range from $130.66 to $131.64. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000016 · wk-form4_1779141028.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · derivative · entry 6

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,110

Underlying: Common Stock · 25,000 shares

Expires 2029-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F6 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,779

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F5 · price: Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,479

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F4 · price: Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,853

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,030

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0000882095-26-000010 · wk-form4_1777927225.xml · derivative · entry 2

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0000882095-26-000010 · wk-form4_1777927225.xml · nonDerivative · entry 1

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,066

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001183680-26-000002 · wk-form4_1777927002.xml · derivative · entry 2

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001183680-26-000002 · wk-form4_1777927002.xml · nonDerivative · entry 1

BARTON JACQUELINE K · CIK 0001183680 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,202

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001188919-26-000004 · wk-form4_1777926511.xml · derivative · entry 2

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001188919-26-000004 · wk-form4_1777926511.xml · nonDerivative · entry 1

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,484

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001213307-26-000003 · wk-form4_1777926175.xml · derivative · entry 2

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.